Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 152 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diabetic Neuropathies, Painful Clear all
Completed Phase 3 Interventional Results available

Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy

NCT04469270
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
Engensis, Placebo
Biological · Other
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
16
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy

NCT00857623
View directory record Official record
Conditions
Pain, Diabetic Neuropathy
Interventions
AZD2066, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
19
States / cities
Bella Vista, Arkansas • National City, California • Walnut Creek, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2012 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

Study of DA-9801 to Treat Diabetic Neuropathy

NCT01822925
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
DA-9801 300mg, DA-9801 600mg, DA-9801 900mg, Placebo
Drug
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
Lakewood, California • Walnut Creek, California • Milford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Sep 24, 2026, 4:02 PM EDT
Not listed Phase 4 Interventional

Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy

NCT00123136
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
foot energizer
Device
Lead sponsor
Weintraub, Michael I., MD, FACP, FAAN
Individual
Eligibility
18 Years to 90 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Briarcliff, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2006 · Synced Sep 24, 2026, 4:02 PM EDT
Terminated Phase 3 Interventional Results available

A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)

NCT01063868
View directory record Official record
Conditions
Diabetic Neuropathy, Painful, Diabetic Polyneuropathy
Interventions
Tapentadol extended release (ER), Oxycodone controlled release (CR)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
23
States / cities
Mesa, Arizona • Tucson, Arizona • Fruitland Park, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Sep 24, 2026, 4:02 PM EDT
Terminated Phase 4 Interventional Results available

Spinal Cord Stimulation for Painful Diabetic Neuropathy

NCT00487981
View directory record Official record
Conditions
Diabetic Neuropathy, Pain, Peripheral Neuropathy
Interventions
Precision Spinal Cord Stimulation
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain

NCT00507936
View directory record Official record
Conditions
Diabetic Neuralgia, Diabetic Neuropathies, Diabetic Neuropathy, Painful, Diabetic Polyneuropathy, Neuralgia, Diabetic
Interventions
ABT-894, placebo, Duloxetine
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 24, 2026, 4:02 PM EDT
Active, not recruiting Not applicable Interventional

Cryoneurolysis for Painful Diabetic Neuropathy of the Foot

NCT06646731
View directory record Official record
Conditions
Painful Diabetic Peripheral Neuropathy (PDPN)
Interventions
cryoneurolysis, sham cryoneurolysis
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Gene Therapy for Painful Diabetic Neuropathy

NCT02427464
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
Interventions
Engensis (VM202), placebo
Biological · Other
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
25
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Gatos, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy

NCT01086150
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Skin biopsy, Lidocaine 5% patches
Procedure · Drug
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)

NCT00592904
View directory record Official record
Conditions
Neuralgia
Interventions
E2007
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Sep 24, 2026, 4:02 PM EDT
Terminated Phase 2 Interventional

A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

NCT00993018
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
JNJ-42160443 (1 mg), JNJ-42160443 (3 mg), JNJ-42160443 (10 mg), Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
23
States / cities
Jonesboro, Arkansas • Fresno, California • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 3 Interventional

A Study for the Treatment of Painful Diabetic Neuropathy

NCT00058968
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
Duloxetine hydrochloride, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Pembroke Pines, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2007 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain

NCT00343733
View directory record Official record
Conditions
Pain
Interventions
OraVescent Fentanyl
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
21
States / cities
Hot Springs, Arkansas • Los Gatos, California • Oxnard, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)

NCT00643760
View directory record Official record
Conditions
Neuropathy, Diabetic
Interventions
Placebo, GEn 1200mg/day, GEn 2400mg/day, GEn 3600mg/day, Pregabalin
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
90
States / cities
Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2013 · Synced Sep 24, 2026, 4:02 PM EDT
Terminated Phase 2 Interventional

Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy

NCT02372578
View directory record Official record
Conditions
Painful Diabetic Peripheral Neuropathy (PDPN)
Interventions
ASP3662, pregabalin, ASP3662 placebo, pregabalin placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
37
States / cities
Anniston, Alabama • Phoenix, Arizona • Fresno, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 24, 2026, 4:02 PM EDT
Not listed Not applicable Interventional

An Evaluation of an SCCD on the Symptomatology of Painful DPN

NCT03331614
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
Flowaid FA-100 SCCD
Device
Lead sponsor
Rosenblum, Jonathan I., DPM
Individual
Eligibility
18 Years to 90 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lodi, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 2Phase 3 Interventional

A Trial to Assess the Efficacy and Safety of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy

NCT00235469
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
SPM 927
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
496 participants
Timeline
2004 – 2005
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 3 Interventional

Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain

NCT00228605
View directory record Official record
Conditions
Low Back Pain, Migraine, Diabetic Neuropathies, Osteoarthritis
Interventions
OraVescent Fentanyl
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
38
States / cities
Calera, Alabama • Hoover, Alabama • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Not applicable Interventional Results available

Dual Field PEMF Therapy in Lower Extremity Painful Diabetic Distal Symmetric Peripheral Neuropathy

NCT03455543
View directory record Official record
Conditions
Diabetic Neuropathy Peripheral
Interventions
Active Provant Therapy System, Inactive (sham) Provant Therapy System
Device
Lead sponsor
Regenesis Biomedical, Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
18
States / cities
Mesa, Arizona • Northridge, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 2 Interventional

A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy

NCT04786340
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetes Mellitus
Interventions
Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution, Placebo: WST-057 4mL topical solution
Drug
Lead sponsor
WinSanTor, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2a Study to Assess Safety & Pharmacokinetics of Sustained Release Sodium Nitrite in Patients With Diabetic Pain

NCT02412852
View directory record Official record
Conditions
Diabetes
Interventions
Sodium nitrite, Placebo
Drug
Lead sponsor
TheraVasc Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Centerville, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN

NCT04857957
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
Oral dose CNTX-6016 or oral dose Placebo
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
18 Years to 59 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 24, 2026, 4:02 PM EDT
Recruiting Phase 2 Interventional

SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.

NCT06614322
View directory record Official record
Conditions
Painful Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain (DPN), Chemotherapy Induced Peripheral Neuropathy (CIPN), Idiopathic Peripheral Neuropathy
Interventions
Pregabalin, Duloxetine, Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Boston, Massachusetts • New York, New York • Rochester, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 24, 2026, 4:02 PM EDT